Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease.

Aliment Pharmacol Ther

Inserm U954 and Department of Gastroenterology, Nancy University Hospital, Henri Poincaré University, Vandoeuvre-lès-Nancy, France.

Published: October 2015

Download full-text PDF

Source
http://dx.doi.org/10.1111/apt.13335DOI Listing

Publication Analysis

Top Keywords

letter infliximab
4
infliximab de-escalation
4
de-escalation based
4
based trough
4
trough levels
4
levels patients
4
patients inflammatory
4
inflammatory bowel
4
bowel disease
4
letter
1

Similar Publications

Treatment with infliximab and tacrolimus in steroid-refractory pneumonitis secondary to anti-HER2 therapy.

ESMO Open

January 2025

The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool; Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK. Electronic address:

View Article and Find Full Text PDF

Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis - Authors' reply.

Lancet Gastroenterol Hepatol

January 2025

Department of Gastroenterology, Austin Health, Melbourne, VIC, Australia; Department of Medicine (Austin Health), University of Melbourne, Melbourne, VIC, Australia. Electronic address:

View Article and Find Full Text PDF

Intensified infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.

Lancet Gastroenterol Hepatol

January 2025

Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven 3000, Belgium. Electronic address:

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!